Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dehydrated human amnion membrane (dHAM) is a tissue-based allograft derived from the innermost layer of the human placenta. It is processed using proprietary methods, such as the PURION® process, to create a stable, dehydrated graft that preserves the natural extracellular matrix (ECM), growth factors, and cytokines essential for tissue regeneration. dHAM serves as a biological scaffold that promotes cell migration and proliferation while providing a protective barrier for wounds. It is primarily utilized in the management of chronic, non-healing wounds like diabetic foot ulcers and venous leg ulcers, as well as in surgical settings to reduce inflammation and scarring, such as in postprostatectomy nerve protection and Mohs micrographic surgery reconstruction.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dehydrated human amnion membrane.